PDCD1 and cancer: GSEA demonstrates that low-risk BRCA patients are related to “Cancer immunotherapy by PD1 blockade,” “ESR mediated signaling,” “Estrogen dependent gene expression,” and “Interferon gamma signaling,” while high-risk BRCA patients are related to “Cell cycle” (Fig. 5J).